Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 4.58% and Operating profit at 1.59% over the last 5 years
2
Flat results in Mar 25
3
With ROE of 11.85%, it has a attractive valuation with a 0.92 Price to Book Value
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 16,108 Million (Large Cap)
8.00
NA
3.75%
-0.28
11.85%
0.92
Revenue and Profits:
Net Sales:
12,890 Million
(Quarterly Results - Jun 2025)
Net Profit:
506 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.04%
0%
-4.04%
6 Months
-16.05%
0%
-16.05%
1 Year
-14.98%
0%
-14.98%
2 Years
-21.95%
0%
-21.95%
3 Years
10.8%
0%
10.8%
4 Years
-14.0%
0%
-14.0%
5 Years
-9.56%
0%
-9.56%
China National Medicines Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.58%
EBIT Growth (5y)
1.59%
EBIT to Interest (avg)
60.23
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.31
Sales to Capital Employed (avg)
2.62
Tax Ratio
24.71%
Dividend Payout Ratio
30.18%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
22.18%
ROE (avg)
14.07%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
0.92
EV to EBIT
5.63
EV to EBITDA
5.00
EV to Capital Employed
0.89
EV to Sales
0.22
PEG Ratio
NA
Dividend Yield
3.75%
ROCE (Latest)
15.83%
ROE (Latest)
11.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
12,889.90
12,686.10
1.61%
Operating Profit (PBDIT) excl Other Income
506.70
538.40
-5.89%
Interest
5.10
9.90
-48.48%
Exceptional Items
0.00
0.00
Consolidate Net Profit
506.40
485.10
4.39%
Operating Profit Margin (Excl OI)
34.40%
37.50%
-0.31%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is 1.61% vs 1.26% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 4.39% vs -12.58% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
50,468.10
49,581.30
1.79%
Operating Profit (PBDIT) excl Other Income
2,352.80
2,575.60
-8.65%
Interest
48.00
143.00
-66.43%
Exceptional Items
-17.50
10.80
-262.04%
Consolidate Net Profit
2,129.80
2,334.50
-8.77%
Operating Profit Margin (Excl OI)
41.70%
47.70%
-0.60%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 1.79% vs 9.24% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -8.77% vs 9.67% in Dec 2023
About China National Medicines Co., Ltd. 
China National Medicines Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






